CTMX Q3 2019 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CTMXCytomX Therapeutics, Inc.

$822M

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$11M-14.4% YoY

Gross Profit

$11M100.0% margin

Operating Income

-$26M-240.1% margin

Net Income

-$24M-221.2% margin

EPS (Diluted)

$-0.52

QoQ Revenue Growth

+18.9%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$24M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$373M

Total Liabilities

$290M

Stockholders' Equity

$82M

Cash & Equivalents

$165M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11M	$13M	-14.4%
Gross Profit	$11M	$13M	-14.4%
Operating Income	-$26M	-$23M	-11.0%
Net Income	-$24M	-$23M	-1.1%